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Abstract
Background: Protease-Activated Receptors (PARs), members of G-protein-coupled receptors, are activated by
proteolytic activity of various proteases. Activation of PAR1 and PAR2 triggers innate immune responses in human
oral keratinocytes (HOKs), but the signaling pathways downstream of PAR activation in HOKs have not been clearly
defined. In this study, we aimed to determine if PAR1- and PAR2-mediated signaling differs in the induction of
innate immune markers CXCL3, CXCL5 and CCL20 via ERK, p38 and PI3K/Akt.
Results: Our data show the induction of innate immunity by PAR1 requires both p38 and ERK MAP kinases, while
PAR2 prominently signals via p38. However, inhibition of PI3K enhances expression of innate immune markers
predominantly via suppressing p38 phosphorylation signaled by PAR activation.
Conclusion: Our data indicate that proteases mediating PAR1 and PAR2 activation differentially signal via MAP
kinase cascades. In addition, the production of chemokines induced by PAR1 and PAR2 is suppressed by PI3K/Akt,
thus keeping the innate immune responses of HOK in balance. The results of our study provide a novel insight
into signaling pathways involved in PAR activation.
Background
Protease-activated receptors (PARs) are G-protein-
coupled receptors (GPCRs) with a unique mechanism of
activation. These receptors carry their own tethered
ligands and are activated by proteolytic activity of serine
proteases [1]. Among the four members of the PAR
family, PAR1 and PAR2 are highly expressed in human
oral keratinocytes (HOKs) [2]. PAR1 is activated by
thrombin and PAR2 is activated by trypsin-like enzymes,
including trypsin, mast cell tryptase and neutrophil pro-
teinse-3 [3]. Activation of PARs by proteases of patho-
gens Porphyromonas gingivalis and Aggregatibacter
actinomycetemcomitans, the Gram-negative bacteria
associated with periodontitis, suggests a role for PARs
and particularly PAR2 as a putative mediator of period-
ontitis [2,4-7].
Periodontitis is an infection of periodontal tissues
which are the supportive structure for the teeth. In the
complex structure of periodontal tissues, gingival epithe-
lium is the first layer which encounters various perio-
pathogens, acting as a physical barrier and playing an
active role in innate immunity [8,9]. Oral keratinocytes
utilize PAR1 and PAR2 as part of their ability to sense
their environment, and activation of these receptors
induces up-regulation of several cytokines, chemokines
as well as antimicrobial peptides [2,10,11].
Findings from our earlier study showed that activation of
PARs induced expression of CXCL3/MIP-2b, CXCL5/
ENA-78 and CCL20/MIP-3a in HOKs [12]. CXCL3 and
CXCL5 stimulate the chemotaxis of monocytes and neu-
trophils and both interact with the chemokine receptor
CXCR2 [13]. CCL20 is strongly chemotactic for lympho-
cytes and dendritic cells and elicits its effect by activating
chemokine receptor CCR6 [14]. These findings suggest
that the major function of PAR1 and PAR2 in oral kerati-
nocyte is to initiate and prolong innate immune responses
via attraction of cells of the immune system such as leuko-
coytes and dendritic cells. Understanding the signaling
pathways downstream of PAR1 and PAR2 activation lead-
ing to such responses will help us better understand how
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In the current work, we studied differential signaling
of PAR1- and PAR2-mediated innate immune responses
in the induction of CXCL3, CXCL5 and CCL20 via
ERK, p38 and PI3K/Akt signaling. We hypothesized that
the induction of these markers by PAR1 and PAR2 is
differentially mediated by activation MAPK and PI3K,
and used selective inhibitors for components of these
signaling pathways to study their effects on PAR signal-
ing. The results provide a novel insight into signaling
pathways involved in PAR activation.
Methods
Primary HOKs isolation and cell culture
Tissue preparation and cell culture method for primary
HOKs have been described previously in detail [9].
Briefly, healthy gingival tissue samples from patients
undergoing third molar extraction were collected for tis-
sue culture with patients’ informed consent and accord-
ing to the procedures approved by University of
Washington Institutional Review-Board. Tissue samples
were processed to dissociate the epithelium into single
cells. For experiments, cells were grown in supplemen-
ted serum-free keratinocyte basal medium (KBM)
(Cambrex, Walkersville, MD) and incubated at 37°C in
5% CO2. Fourth passage cells at 75-80% confluence
were used for all experiments. Due to the possible varia-
tion between individual donors, we looked for consistent
results in HOKs from at least three donors with techni-
cal duplicate for each set of experiments, unless other-
wise stated.
Reagents used
Human alpha-thrombin (Haematologic Technologies
Inc, Essex Junction,VT) and recombinant human trypsin
(Polymun Scientific Immunobiologische Forschung
GmbH, Austria) were used to stimulate HOKs in order
to activate PAR1 and PAR2, respectively. D-Phe-Pro-
Arg-chloromethyl ketone dihydrochloride (PPACK-HCL,
Calbiochem, La Jolla, CA) and serine protease inhibitor,
tosyl-L-lysine chloromethyl ketone (TLCK, Sigma, St.
Louis, MO) were used to inhibit thrombin and trypsin,
respectively. Inhibitors for ERK1/2 (U0126) and its con-
trol substance (U0124), p38 (SB203580), PI3K (Wort-
mannin and LY294002), Akt (Akt inhibitor IV) were
from Calbiochem (La Jolla, CA). Rabbit polyclonal p38
MAPK (9212) and Akt (9272), and monoclonal phos-
pho-p38 MAPK (Thr180/Tyr182; D3F9), phospho-Akt
(Thr308; 244F9), p44/p42 MAPK (ERK1/2; 137F5), and
phospho-p44/p42 MAPK (Thr202/Tyr204;D13.14.4E,
XP™) antibodies were obtained from Cell Signaling
Technology, Inc. (Danvers, MA). Mouse monoclonal
GAPDH, used as western blot control for equal gel load
of protein, was purchased from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA). As assessed by the Limulus
Amebocyte Lysate Pyrotell (Cape Cod Inc., Falmouth,
MA), the thrombin (1 U/ml) and trypsin (1 nM)
preparations in our study contained less than 0.03 EU
LPS/ml.
RNA isolation, reverse transcription and Quantitative
RT-PCR (QRT-PCR)
S i n g l e - s t r a n d e dc D N Aw a ss y n t h e s i z e df r o mt o t a lR N A
and used to perform QRT- PCR with gene-specific pri-
mers as described previously [6,12]. Unstimulated HOKs
and samples without RT served as negative controls.
A melting curve was performed at the end of each
QRT-PCR to ensure the gene product was specific. Gly-
ceraldeyde-3-phosphate dehydrogenase (GAPDH) was
used as the selected housekeeping gene for normaliza-
tion. The primer sequences for GAPDH, CXCL5,
CXCL3 and CCL20 have been described previously
[6,12,15]. Data were analyzed using Pfaffl method to cal-
culate fold change of gene expression [16].
Measurement of chemokines in culture supernatant
Secreted CXCL5 and CCL20 were measured in culture
supernatant using Duoset ELISA kit (R&D, Minneapolis,
MN). The absolute concentration in each sample was
calculated based on sample yielding optical density
using the standard curve. Chemokine secretion from
each condition was normalized to chemokine produced
at baseline level in unstimulated control group, and
results are presented as percent of unstimulated control
cells.
ELISA assay for quantification of p38 and ERK1/2
phosphorylation
To assess phosphorylation of p38 and ERK1/2, treated
cells were homogenized in lysis buffer in accordance
with the manufacturer’s protocol (R&D). Immediately
prior to adding to cells, protease and phosphatase inhi-
bitors, PMFS and sodium orthovanadate (Santa Cruz
Biotechnology), Halt Protease Inhibitor Cocktail and
Halt Phosphatase Inhibitor Cocktail (Pierce, Rockford,
IL), were added to the lysis buffer. Phosphorylation of
p38 and p42/44 (ERK1/2) was assessed in cell lysate
using Duoset antibody pairs following manufacturer’s
protocol (R&D). Total p38 was quantified by a similar
method (R&D) and served for normalization. Total p38
was proportional to total protein measured in each sam-
ple and to the number of cells plated in each well.
Western blot analysis
Total and phosphorylated kinase expression in untreated
and agonist-stimulated HOK cells was determined by
Western immunoblot analysis. Samples of whole cell
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LSD sample and reducing buffer, were resolved conco-
mitantly with Precision Plus Dual Color protein molecu-
lar weight standard (Bio-Rad, Hercules, CA) in NuPAGE
4-12% Bis-Tris mini gel (1.5 mm, 10 well) and MOPS
SDS running buffer in XCell SureLock Mini-Cell, trans-
ferred to PVDF membrane (Immobilon-P, Millipore,
Chicago, Il) in XCell II Blot Module using electrophor-
esis systems and protocols of InVitrogen Corp.
(Carlsbad, CA). PVDF membranes were blocked for 1 h
with 1% BSA, 1%PVP and 1% PEG in wash buffer (0.1%
Tween-20, 100 mM Tris/HCl, 20 mM NaCl), then: (1)
incubated with rabbit primary antibodies either over-
n i g h ta t4 ° Cf o rp h o s p h o - A k ta n t i b o d y ,o r1ha tr o o m
temperature for total (Akt, p38 MAPK and p44/p42
MAPK) and phospho- proteins (p38 MAPK, and p44/
p42 MAPK) at concentrations recommended by the
manufacturer, then incubated for 1 h with donkey anti-
rabbit IgG (H+L) HRP conjugate (Jackson ImmunoRe-
search, West Grove, PA) diluted 1:20,000 in 0.1%
Tween-20, Tris Buffered Saline (TBS); or (2) incubated
with mouse monoclonal GAPDH diluted 1:5,000 in
blocking buffer and then with goat anti-mouse IgG
(H+L) HRP conjugate (JacksonImmunoResearch) diluted
1:50,000 in 0.1%TTBS. Secondary antibody binding to
primary antibody was detected using SuperSignal West
Dura Extended Duration chemiluminescent substrate
and protocols of Thermo Scientific (Rockford, IL). Film
exposures were chosen to give unsaturated blot densi-
ties. GAPDH immunoblots showing equal gel load of
protein were obtained without stripping. Total protein
immunoblots for Akt, p38 MAPK and p44/p42 MAPK
were obtained from separate gels loaded with 2 to 5 fold
less protein. Chemiluminograms of immunoblots were
digitally scanned and saved in TIFF format using Photo-
shop™ software (Adobe System Inc., San Jose, CA) with-
out further processing.
Statistical analysis
Data collected from at least three donors are presented
as mean ± standard error of the mean (S.E.M). Data
were compared using one-way ANOVA followed by
Bonferroni post test. A p-value < 0.05 was considered to
be significant.
Results
Activation of PARs modulates phosphorylation of ERK1/2
and p38 in primary HOKs
We examined the dynamic activation of ERK1/2 and
p38 when cells were stimulated with thrombin and tryp-
sin. ELISA-based analysis showed a transient weak and
rapid (5 min) phosphorylation of ERK1/2 subsequent to
both PAR1 and PAR2 activation. In PAR1-activated
cells, the level of ERK1/2 activity was at its maximum
within 5 min and then decreased and remained at a
steady level close to baseline up to 90 min. In contrast,
after its maximum phosphorylation at 5 min, PAR2 acti-
vation induced dephosphorylation of ERK1/2 to below
the baseline level for up to 90 min (Figure 1a). Both
PAR1 and PAR2 activation also induced phosphoryla-
tion of p38 within 5 min (Figure 1b). The activation of
p38 increased steadily and reached a maximum at 15-30
min. However, PAR2 activation resulted in a higher
level of p38 phosphorylation than with PAR1 activation
(Figure 1b). These results were confirmed by Western
immunoblot analysis as well. Neither PAR1 nor PAR2
was a strong inducer of ERK1/2 phosphorylation, either
at times shorter than 5 min or between 5-60 min after
stimulation (Figure 1c). A striking change in phospho-
ERK1/2 is induced by PAR2 activation, which causes
d e p h o s p h o r y l a t i o no fp h o s p h o - E R K 1 / 2i n1 5m i n .I n
accordance with ELISA results, both PAR1 and PAR2
activation induced p38 phosphorylation, which was sus-
tained up to 60 min (Figure 1c, second row). We next
tested the effect of PAR1 and PAR2 activation on phor-
phorylation of Akt (also known as protein kinase B,
PKB). Akt is a serine/threonine protein kinase and acti-
vated by stimuli that induce production of phosphatidy-
linositol (3,4,5)-trisphosphate via activation of PI3K [17].
Results show a rapid phosphorylation of Akt in effect of
PAR1 and PAR2 activation (Figure 1d). These results
suggest involvement of MAP kinases and PI3K/Akt in
cellular signaling downstream of PAR activation and
identify distinct patterns of ERK1/2 and p38 MAPK
phosphorylation by PAR1 and PAR2. Phosphorylation of
ERK1/2 was subtle and transient, while p38 phosphory-
lation was prolonged. The kinetic analysis suggests
ERK1/2 is more involved in PAR1 signaling, while p38
has greater participation in PAR2 signaling.
The innate immune markers induced by PAR1 and PAR2
activation are regulated by ERK1/2 and p38 MAPK
In our previous studies we found that thrombin induced
CXCL3 and CXCL5 via PAR1, while trypsin induced
up-regulation of CXCL3, CXCL5 and CCL20 via PAR2
activation [12]. In this study, we investigated the signal-
ing molecules involved in the induction of these innate
immune markers following PAR1 and PAR2 activation
in HOKs. As activation of PAR1 and PAR2 modulates
phosphorylation of p38 and ERK1/2, next we analyzed
the role of ERK1/2 and p38 in the PAR1- and PAR2-
induced CXCL3, CXCL5 and CCL20 mRNA expression.
Inhibition of ERK1/2 by U0126, which inhibits the sig-
naling molecule upstream of ERK1/2, significantly
blocked the expression of CXCL3 and CXCL5 induced
by PAR1 activation, but had no significant effect on the
induction of the three markers by PAR2 activation
(Figure 2a-b). Inhibition of p38 by SB203580 had a
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PAR1-induced CXCL3, but the effect was attenuated at
higher concentration (20 μM). In the presence of the
p38 inhibitor, PAR1-activated cells showed a decrease in
CXCL5 expression in a dose-dependent manner but
there was no effect on CCL20 expression (Figure 2c). In
contrast, induction of all three markers by PAR2 activa-
tion was significantly blocked by the p38 inhibitor in a
dose-dependent manner (Figure 2d). The inhibitors on
their own did not affect the expression of the selected
markers (data not shown). Furthermore, the efficacy of
the inhibitors was tested. Immunoblot analysis showed a
reduction in phosphorylation of ERK1/2 and p38 in the
presence of U0126 and SB203580, respectively (Figure
2e-f). These results suggest that both ERK1/2 and p38
are activated downstream of PARs signaling to induce
Figure 1 The effect of PAR activation on the kinetics of ERK1/2, p38 and Akt phosphorylation. HOKs were stimulated with thrombin (10
U/ml) or trypsin (10 nM) for 0-90 min. (a-b) Phosphorylation of ERK1/2 and p38 was quantified in cell lysates using ELISA. Data are given as
percent of unstimulated cells and as means ± S.E.M from two different donors. (*p < 0.05 compared to unstimulated control at 0 min). (c-d) The
Western blots analysis of whole cell lysates from cells stimulated with thrombin (10 U/ml) or trypsin (10 nM) at indicated times. Cell lysates were
analyzed by immnoblotting with specific antibodies to phospho-ERK1/2, total ERK1/2, phospho-p38, total p38, phospho-Akt and total Akt.
GAPDH was served as a control to verify equal loading and transfer of samples.
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Page 4 of 12Figure 2 PAR1 and PAR2 signal via ERK1/2 and p38 MAP kinases to induce expression of innate immune markers.( a - b )H O K sw e r e
incubated with a selective inhibitor for ERK1/2 and its control substance, U0126 and U0124, respectively, at 500 nM or (c-d) a p38 inhibitor,
SB203580 at 2-20 μM for 1 h, then stimulated with thrombin (10 U/ml) or trypsin (10 nM) for 6 h. The mRNA expression of CXCL3, CXCL5 and
CCL20 was measured by QRT-PCR. Data from three different donors set up in duplicates were normalized to GAPDH. Data are given as means of
normalized samples to unstimulated control ± SEM. (*p < 0.05 compared to the same condition without inhibitors). (e-f) To test the efficacy of
inhibitors, HOKs were incubated with U0126 (0.5 μM) or SB203580 (20 μM) for 1 h, and then stimulated with thrombin (10 U/ml) for 2 min or
trypsin (10 nM) for 15 min. The Western blot analysis was done using antibodies specific for phospho- ERK1/2, total-ERK1/2, phospho-p38 and
total-p38. GAPDH was used as a control for equal loading of samples.
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selected markers of innate immunity induced by PAR1
activation is more dependent on ERK1/2. In contrast,
PAR2 signaling is more dependent on p38 in the induc-
tion of innate immune responses.
Innate immune expression in response to PAR1 and PAR2
activation is enhanced by PI3K/Akt inhibition
The PI3K/Akt signaling pathway plays a role in coordi-
nating defense mechanisms in innate immunity [18,19].
Increased phosphorylation of Akt suggested activation of
PI3K/Akt pathway downstream of PARs. In order to
determine its role in the regulation of selected innate
immune markers mediated via PAR1 and PAR2, we
used selective inhibitors for PI3K. Inhibition of PI3K by
two specific inhibitors, Wortmannin (Figure 3a-b) and
LY294002 (data not shown), induced a concentration-
dependent enhancement of CXCL3, CXCL5 and CCL20
mRNA expression in PAR1- and PAR2-activated cells,
thus suggesting that PI3K has an inhibitory effect on
innate immune responses induced by both PAR1 and
PAR2. In order to confirm this negative regulatory effect
of PI3K, we tested the effect of blocking Akt on
responses induced by PAR1 and PAR2 activation. Block-
ing Akt activity by Akt inhibitor IV, which inhibits a
kinase upstream of Akt but downstream of PI3K, also
resulted in an increase in expression of all three markers
induced by PAR1 at higher doses of inhibition, and
increased CCL20 expression induced by PAR2 activation
(Figure 3c-d). These results suggest that the PI3K/Akt
signaling pathway limits the innate immune responses
activated by PAR1 and PAR2.
Secretion of CXCL5 in response to PAR1 and PAR2
activation is enhanced by PI3K/Akt inhibition
A previous study reported inhibitory effect of PI3K
signaling pathways following activation of Toll-like
receptor 4 by LPS [20]. In our studies we confirmed no
endotoxin contamination in thrombin and trypsin. How-
ever, in order to exclude the possibility that endotoxin
Figure 3 Expression of PAR1- and PAR2-induced innate immunity is enhanced when PI3K/Akt signaling pathway is blocked. HOKs were
incubated with inhibitors for PI3K (Wortmannin) at 25-400 nM (a-b) or for Akt (Akt inhibitor IV) at 0.5-2.5 uM (c-d) for 1 h and subsequently
stimulated with thrombin (10 U/ml) or trypsin (10 nM) for 6 h. Cells were harvested and expression of the selected markers was assessed by
QRT-PCR. Data from three separate donors set up in duplicates were normalized to GAPDH. Data are given as means of normalized samples to
unstimulated control ± SEM. (*p < 0.05 compared to the same condition without inhibitors).
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increased expression of innate immune markers, and also
to test if increased induction of selected markers is asso-
ciated with the secretion of mature proteins, we mea-
sured CXCL5 and CCL20 in culture supernatant when
cells are stimulated with thrombin and trypsin for PAR1
and PAR2 activation, respectively, or with the inactivated
form of the enzymes in the presence of PI3K inhibitor.
CXCL5 secretion induced by PAR1 activation was
increased when PI3K activity was inhibited, and this
effect was abrogated in the presence of PPACK to block
thrombin proteolysis. A similar pattern was observed for
secreted CXCL5 induced by PAR2 activation, and the
effect was abrogated in the presence of TLCK to inhibit
trypsin. However, secreted level of CCL20 did not change
significantly in the presence of the PI3K inhibitor in
either PAR1- or PAR2-activated cells (Figure 4a-b).
Taken together, our data suggest that PI3K is a negative
regulator of innate immune markers induced by activa-
tion of PAR1 and PAR2.
Inhibition of PI3K is associated with decreased ERK1/2
and increased p38 phosphorylation
Since activation of MAPK and PI3K signal transduction
had opposite effects on innate immune responses
induced by PAR activation in HOKs, we hypothesized
that PI3K has inhibitory effect on activation of ERK1/2
and p38 downstream of PAR1 and PAR2 signaling. We
assayed the phosphorylation of ERK1/2 at 5 min and
p38 at 30 min (the time of maximum phosphorylation
of ERK1/2 or p38) when PI3K activity was inhibited by
Wortmannin at various concentration and cells were sti-
mulated with thrombin or trypsin for PAR activation.
ELISA-based assay suggested that in these conditions,
inhibition of PI3K by Wortmannin followed by PAR1 or
PAR2 activation caused decreased phosphorylation of
ERK1/2 in a dose-dependent manner (Figure 5a-b). In
contrast, inhibition of PI3K increased phosphorylation
of p38 in response to PAR activation, and these effects
were correlated with increased concentration of PI3K
inhibitors (Figure 5c-d). Inhibition of PI3K by LY294002
had similar effects as Wortmannin on cells activated
with trypsin, but had less potent effects on cells acti-
vated with thrombin (data not shown). These findings
were confirmed by Western immunoblot analysis as
well. As shown in Figure 5e, inhibition of PI3K activity
by Wortmannin decreased phosphoylation of ERK1/2,
but increased p38 phosphorylation when PAR1 and
PAR2 are activated. Moreover, the efficacy of Wortman-
n i ni ni n h i b i t i o no fP I 3 Ki ss h o w nb yd e c r e a s e dA k t
phosphorylation, downstream of PI3K (Figure 5e). These
results suggest that PAR1 and PAR2 activation leads to
a crosstalk between activation of PI3K, ERK1/2 and
p38, and that inhibition of PI3K results in decreased
activation of ERK1/2 but increased activation of p38
downstream of PAR signaling.
Discussion
The transmission of signals from cell membrane into
the nucleus requires coordinated action of diverse sig-
naling proteins. In this study we identified the key sig-
naling molecules involved in the induction of innate
immunity in human oral keratinocytes in response to
PAR1 and PAR2 activation. PAR1 and PAR2 have been
demonstrated to activate members of the MAPK signal-
ing cascade in the induction of IL-8 and IL-1b in epithe-
lial cells from different tissue origin [21-24]. In
agreement with these reports, our findings indicated
both p38 and ERK1/2 were phosphorylated by PAR1
and PAR2 activation. Our findings further reveal that
the induction of additional innate immune markers,
CXCL3, CXCL5 and CCL20, upon activation of PAR1
and PAR2 signals via p38 and ERK1/2. However, we
observed divergent role for ERK1/2 and p38 MAPK in
transducing signals for innate immunity by PAR1 and
PAR2. PAR1 signals via both p38 and ERK1/2, whereas
the induction of similar chemokines by PAR2 is primar-
ily via p38. We also showed that PI3K activation had a
negative regulatory role for both PAR1 and PAR2 sig-
naling and thus may limit proinflammatory responses
induced by proteases in the environment.
Our kinetics studies demonstrated transient ERK1/2
phosphorylation by PAR1 and PAR2 activation, which was
followed by a distinct pattern of ERK1/2 dephosphoryla-
tion. This was more prominent with PAR2 activation com-
pared to PAR1 activation. This may explain the minimum
effect of inhibition of ERK1/2 for PAR2-mediated innate
immune responses. On the other hand, PAR2 activation,
compared to PAR1, resulted in more effective phosphory-
lation of p38. These data suggest that dephosphorylation
of ERK1/2 following PAR2 activation may be a protective
mechanism against excess innate immune responses via
p38 and ERK1/2. A similar protective effect by down-regu-
lation of MAPK signaling downstream of PAR2 activation
is reported in acute pancreatitis induced by an intraperito-
neal injection of caerulein in rats [25]. However, the
mechanism of ERK dephosphorylation by PAR2 activation
is still unclear, and we are investigating whether PAR2 sig-
naling mediates activation of phosphatases or if other
mechanisms are involved.
Inhibition of p38 also differentially affected the expres-
sion of selected markers induced by PAR1 and PAR2
activation with different sensitivity to the presence of
inhibitor for each marker. This may be related to the
involvement of different p38 subunits (a,b,g,δ)w i t h
differential downstream signaling and also to the lack of
the equipotency of the current inhibitor against all
subunits [26].
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Page 7 of 12Figure 4 PAR-induced secretion of CXCL5 is increased when PI3K is inhibited. HOKs were incubated with Wortmannin at 25-400 nM for 1
h. Then cells were stimulated with thrombin (10 U/ml), trypsin (10 nM) or inactivated form of thrombin and trypsin by using PPACK (180 nM)
and TLCK (10 μM), respectively, for additional 1 h. Subsequently cells were washed and incubated in fresh medium for 24 h. CXCL5 and CCL20
were measured in the culture supernatant using ELISA. Data are representative of two separate experiments using cells from different donors.
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PAR signaling in HOKs. This effect was shown most
clearly at the mRNA level and also for CXCL5 at protein
level. We did not observe this effect in the secretion of
CCL20, which may be related either to the peptide struc-
ture of CCL20 which is vulnerable to proteolytic activity
of enzymes, or to involvement of other mechanisms that
affect CCL20 expression at the post-transcriptional level.
Figure 5 Inhibition of PI3K is associated with decreased ERK1/2 and increased p38 phosphorylation. HOKs were pretreated with 25-400
nM Wortmannin for 1 h followed by stimulation with (a,c) thrombin (10 U/ml) or (b,d) trypsin (10 nM). Phospho ERK1/2 at 5 min and phospho
p38 at 15 min after PAR1/PAR2 activation were quantified in cell lysate by ELISA. Data are given as percent of unstimulated cells and as means ±
S.E.M from two different donors. (p < 0.05, * vs. cells treated with thrombin or trypsin in the absence of inhibitors, # vs. Wortmannin 100 nM+
(thrombin or trypsin)). (e) For immunoblot analysis of phospho-ERK1/2 and phospho-p38, HOKs were preincubated with Wortmannin (400 nM)
for 1 h followed by stimulation with thrombin (10 U/ml) or trypsin (10 nM). By using specific antibodies for phosphor-ERK1/2, total ERK1/2,
phosphor-p38 and total-p38, phosphorylation of ERK1/2 and p38 was evaluated at 5 min and 15 min, respectively. To test the efficacy of
Wortmannin in blocking PI3K/Akt pathway, above sample lysates were analyzed by immunoblotting using antibodies specific for phospho-Akt
and total-Akt. GAPDH was used as a control for equal loading of samples.
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signaling in normal human keratinocytes with compar-
able cellular function, but our results indicate HOKs
have a unique signaling system. It has been shown that
thrombin signals via PI3K to induce osteoprotegerin in
human periodontal ligament and VEGF in human pig-
ment retinal epithelial cells [23,27]. In a recent study
Minhajuddin et al. showed that PI3K/Akt is involved in
modulation of NF-B and expression of ICAM-1 induced
by thrombin in endothelial cells. Their study suggested
that activation of PI3K/Akt leads to activation of mTOR.
While the over-expression of the catalytic domain of Akt
increases activation of NF-Bi nt h ea b s e n c eo fm T O R
activity, restoring mTOR signaling dampens activation of
NF-B and induction of ICAM-1 [28]. In an earlier study
by this group it was reported that thrombin-mediated
ICAM-1 induction relies on parallel activation of PI3K
and PKC that converges at Akt and induces activation of
NF-B [29]. In contrast to their findings, our results sug-
gest a direct inhibitory role for PI3K/Akt. These discre-
pancies may be explained by cell type-specific signaling
mechanisms or different markers that have been investi-
gated. Our finding in HOKs suggests PI3K acts as a com-
pensatory mechanism which suppresses inflammatory
responses. A similar inhibitory role for PI3K signaling in
response to TLR2 and TLR5 activation has been reported
in monocytes, dendritic cells and epithelial cells [30-32],
suggesting that PI3K may act as a balancing point to pre-
vent excessive innate immune responses. It has been
reported that PI3K knockout mice compared to their het-
erozygous littermates displayed increased levels of IL-6,
IL-8 and nitrite in response to TLR5 activation [32].
Results from our study suggest that inhibition of PI3K/
Akt resulted in the up-regulation of innate immune mar-
kers CXCL3, CXCL5 and CCL20 via PAR activation in
HOKs.
Our results suggest that the mechanism of crosstalk
between PI3K and PAR signaling is via effect on phos-
phorylation of p38 and ERK1/2. We observed inhibi-
tion of PI3K resulted in increased p38 phosphorylation
even in the absence of external stimulants (thrombin
and tryspin), and this effect was significantly greater
when cells were stimulated with active enzyme versus
inactive form of thrombin and trypsin. This finding
suggested a specific role of PAR activation in the
induction of a crosstalk between PI3K and p38. This
interaction between p38 and PI3K signaling pathways
downstream of PARs activation may serve as a protec-
tive strategy HOKs utilize to keep innate immune
responses in balance. Activation of PI3K inhibits the
induction of proinflammatory chemokines possibly by
suppression of p38 MAPK activation. When TLR5 is
activated by flagellin in intestinal cells [32] and in
VEGF-induced tissue factor in endothelial cells [33],
suppressive effect of PI3K has been observed. Although
we expected to see a similar relationship between
ERK1/2 and PI3K activation, our studies showed block-
ing PI3K limited ERK1/2 activity and suggest that PI3K
and ERK signaling pathways are acting in series. Other
studies showed that inhibition of PI3K induced phos-
phorylation of ERK1/2 in intestinal epithelial cells sti-
mulated with flagellin [32] and in hepatic stellate cells
activated with platelet-derived growth factor [34].
These studies may reflect that the interaction between
PI3K and ERK signaling varies depending on the sti-
mulus and cell type.
Our studies suggested that PAR1 signals via both
E R K 1 / 2a n dp 3 8 ,b u tt h a tE R K 1 / 2h a sam o r ep r o m i -
nent role. However, there was no role for either p38 or
ERK1/2 in the induction of CCL20 by PAR1 activation,
although its expression was increased when PI3K and
A k tw e r ei n h i b i t e d .I ti sl i k e l yt h a ta na l t e r n a t i v e
mechanism, which is independent of the ERK1/2 and
p38 pathways, but still blocked by PI3K, is involved in
the induction of CCL20 by PAR1 activation. This is con-
sistent with our previous study showing that CCL20
induction by thrombin may occur via a mechanism
other than PAR1 [12].
Induction of cytokines and chemokines by PAR activa-
tion leads to infiltration of mononuclear cells in the
microenvironment of periodontal tissue [5]. This process
is part of the initial recognition of danger in the environ-
ment and serves as an important protective function.
While this primary immune response can protect the
body against pathogenic factors, over-activity of these
responses can become destructive and lead to progressive
diseases. In periodontal diseases, exaggerated immune
responses lead to excess inflammation, thus it is poten-
tially important that oral keratinocytes keep immune
responses in balance by shutting down the expression of
proinflammatory genes. It is likely that crosstalk between
p38-MAPK and PI3K/Akt signaling pathways plays a role
in this process. Downstream of PAR activation, PI3K has
as u p p r e s s i v ee f f e c to nt h er egulation of chemokines,
thus may act to minimize the potential negative conse-
quences of over-activity of inflammatory responses. How-
ever, bacterial pathogens with ability to activate PAR
could take advantage of this mechanism in gingival
epithelium and dampen innate immune responses to
increase the survival of pathogens, which will result in
sustained infection. Thus, it is necessary to consider both
sides of the role of PI3K/Akt in evaluating possible thera-
peutic targets. Furthermore, understanding the molecular
events associated with PAR signaling in keratinocytes
may open new possibilities of intervention for mucosal
inflammation such as periodontal diseases.
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We demonstrated in this study that the induction of
inflammatory responses by PAR1 and PAR2 is differen-
tially regulated by ERK1/2 and p38 MAPK signaling
pathways. ERK1/2 and p38 are both involved in signal-
ing via PAR1, but p38 is more critical for signaling via
PAR2. PI3K has a negative regulatory role limiting
proinflammatory gene expression induced by both PAR1
and PAR2. We characterized crosstalk between PI3K/
Akt and MAPK signaling pathways and the possibility of
p38 phosphorylation as one of the mechanisms by
which PI3K keeps innate immune responses in balance
subsequent to PAR activation. A simple schematic over-
view of PAR signaling is summarized in Figure 6.
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